...
首页> 外文期刊>Case Reports in Oncological Medicine >Adjuvant Radiochemotherapy with a 23-Month Overall Survival Time in a Patient after a Surgery due to Splenic Hemangiosarcoma Rupture: A Case Report with the Literature Review
【24h】

Adjuvant Radiochemotherapy with a 23-Month Overall Survival Time in a Patient after a Surgery due to Splenic Hemangiosarcoma Rupture: A Case Report with the Literature Review

机译:脾血管瘤肉瘤破裂手术后患者的辅助放化疗与23个月的总生存时间:文献综述的病例报告

获取原文

摘要

Spleen sarcoma is one of the most rare soft tissue malignancies. The annual incidence is 0.14–0.25/1,000,000 and the average age of diagnosis is 50 to 73 years. The incidence of this cancer has been increasing. Treatment of choice is surgical splenectomy, which rarely gives good results due to the aggressive course of the disease as well as the high potential for metastasis. Overall survival in primary spleen sarcomas as described by various authors is between 4 and 14 months. 80% of patients after spleen rupture do not survive 6 months. We report the case of a 42-year-old male diagnosed with spleen angiosarcoma. The patient underwent surgery in an emergency mode because of rapid rupture of the organ. Due to positive surgical margins, he underwent adjuvant radiochemotherapy followed by chemotherapy. Overall survival time was relatively long (23 months). The international guidelines provide information based on limited data. The role of postoperative radiotherapy in angiosarcomas remains controversial. Postoperative radiotherapy may increase local disease control, especially after nonradical operation, but this does not translate into improvement in overall survival time of these patients. The case shows that adjuvant radiotherapy as part of cancer treatment strategy may prolong the overall survival.
机译:脾肉瘤是最罕见的软组织恶性肿瘤之一。年发病率为0.14-0.25 / 1,000,000,平均诊断年龄为50至73岁。该癌症的发病率一直在增加。选择的治疗方法是手术脾切除术,由于该病的侵袭性病程以及极高的转移潜力,因此很少能获得良好的效果。如不同作者所述,原发性脾肉瘤的总生存时间为4到14个月。脾破裂后80%的患者无法存活6个月。我们报告了一例42岁的男性,被诊断出患有脾血管肉瘤。由于器官快速破裂,患者在紧急模式下接受了手术。由于手术切缘阳性,他接受了辅助放化疗,随后进行了化疗。总体生存时间相对较长(23个月)。国际准则基于有限的数据提供信息。术后放疗在血管肉瘤中的作用仍存在争议。术后放疗可能会增强对局部疾病的控制,尤其是在非根治性手术后,但这并不能转化为这些患者的总生存时间的改善。该病例表明辅助放疗作为癌症治疗策略的一部分可以延长总体生存期。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号